Government Owned Inventions, 84823-84824 [2023-26736]
Download as PDF
<![CDATA[
84823
Federal Register / Vol. 88, No. 233 / Wednesday, December 6, 2023 / Notices
knowledge, skills, and practices both
before (pre) and after (post) completion
of the modules.
CHC Surveys. Conducting online data
collection on participation and use of
NHCI services and supports with CHC
staff, with a single collection for each
survey.
ANNUALIZED BURDEN HOUR TABLE
CHW: Application ................................................................
CHW: Assessment ..............................................................
CHW: Empowered to Serve (ETS) Program Modules: Pretest.
CHW: Empowered to Serve (ETS) Program Modules: Pretest.
CHCs: Use of Azara/Population Health Tool ......................
CHCs: JumpStart Modules ..................................................
CHCs: Uniti Health ..............................................................
CHW ..............
CHW ..............
CHW ..............
300
300
300
1
1
9
30/60
1
10/60
150
300
450
CHW ..............
300
9
10/60
450
CHC ...............
CHC ...............
CHC ...............
40
350
350
1
1
1
1
1
1
40
350
350
Total ..............................................................................
........................
........................
........................
........................
2,090.0
[FR Doc. 2023–26739 Filed 12–5–23; 8:45 am]
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
National Institutes of Health
Dated: December 1, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Center for Scientific Review; Notice of
Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Office of the Director, National
Institutes of Health; Notice of Meeting
Notice is hereby given of a change to
the meeting of the Advisory Committee
to the Director, National Institutes of
Health, that is being held on December
14, 2023, from 9:00 a.m. to 4:45 p.m.,
and December 15, 2023, from 9:00 a.m.
to 2:45 p.m., National Institutes of
Health, 9000 Rockville Pike, Building 1,
Wilson Hall, One Center Drive,
Bethesda, MD 20892, which was
published in the Federal Register on
November 17, 2023, FR Doc 202325376, 88 FR 80320. This notice is being
amended to inform the public that
access to this meeting will be provided
exclusively through live videocast.
Individuals who plan to attend must do
so virtually. The meeting can be
accessed from the NIH Videocast at the
following link: https://
videocast.nih.gov/. The meeting date
and time will remain the same.
Dated: December 1, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–26776 Filed 12–5–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
20:52 Dec 05, 2023
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business for Endocrine, Metabolic Systems
and Reproduction.
Date: December 15, 2023.
Time: 3:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dianne Hardy, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6175,
MSC 7892, Bethesda, MD 20892, 301–435–
1154, dianne.hardy@nih.gov.
This notice is being published less
than 15 days prior to the meeting due
to the timing limitations imposed by the
review and funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
Jkt 262001
Total burden
hours
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4150–29–P
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
Average
burden per
response
Respondents
(if necessary)
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
Number of
respondents
Number of
responses per
respondents
Forms
(if necessary)
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
[FR Doc. 2023–26790 Filed 12–5–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government Owned Inventions
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
directed to a device to measure
placental oxygen saturation in pregnant
women from 20 weeks of pregnancy to
delivery. The device monitors maternal
tissue oxygen saturation, blood oxygen
saturation, breathing rate, heart rate, and
heart rate variability from signal, fetal
movement activity and potentially fetal
heart rate and heart rate variability. This
technology was discovered and is being
developed by the National Institute on
Child Health and Human Development
(NICHD). The NICHD is currently
seeking a licensee and/or collaborator to
further develop this technology.
FOR FURTHER INFORMATION CONTACT:
Inquiries related to this licensing and
collaboration opportunity should be
directed to: Zarpheen Jinnah,
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530, MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702. Telephone: (240)–276–5530;
SUMMARY:
E:\FR\FM\06DEN1.SGM
06DEN1
84824
Federal Register / Vol. 88, No. 233 / Wednesday, December 6, 2023 / Notices
Facsimile: (240)–276–5504; Email:
zarpheen.jinnah@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to this
invention.
SUPPLEMENTARY INFORMATION: The
following patent application is available
for licensing and/or collaboration under
a Cooperative Research and
Development Agreement (CRADA):
US Provisional Application No. 63/
451,066.
Achieving expeditious
commercialization of federally funded
research and development is consistent
with the goals of the Bayh-Dole Act,
codified as 35 U.S.C. 200–212.
lotter on DSK11XQN23PROD with NOTICES1
Background and Description of
Technology
Monitoring placental oxygenation
level and maternal physiological signals
can be useful to assess mother and fetus
well-being during pregnancy.
Additionally, fetal movement has long
served as a measure for fetal well-being
and nervous system development
helping to identify adverse pregnancy
outcomes. Identification of
complications during pregnancy can
allow for earlier interventions,
including medications to reduce risk of
perinatal mortality and maternal gene
therapy. Researchers at NICHD have
created a wearable and wireless device
and protocol for continuously
monitoring the placental oxygenation
levels, multiple physiological signals
and movement activities of a fetus and
mother. The device includes a compact
control board, a flexible near-infrared
spectroscopy (NIRS) probe, and
multiple accelerator probes. A
classification algorithm based on MonteCarlo simulations of multiple layers
model computes oxygen saturation of
the placenta. There are one or more
accelerator probes attached to different
body parts of the mother to detect
mother movement activities and to
eliminate the effect of mother movement
on fetal movement. The overall data
acquisition rate of this device is 10 Hz
or more. With this acquisition rate, the
output of the device contains extra
physiological signal such as maternal
respiratory and cardiac functions, and
fetal cardiac functions.
Potential Commercial Applications
A low cost wearable device, similar to
a smart watch, in which a pregnant
woman can wear regularly to monitor
both mother and fetus health
conditions.
VerDate Sep<11>2014
20:52 Dec 05, 2023
Jkt 262001
Competitive Advantages:
• Wearable and non-invasive placenta
and fetal monitoring device.
• Capable of 24/7 continuous
monitoring of mother and fetal wellbeing.
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
Anna P. Guido, Reports Management
Officer, REE, Department of Housing
and Urban Development, 451 7th Street
SW, Room 8210, Washington, DC 20410;
email: PaperworkReductionActOffice@
hud.gov. telephone (202)-402–5535.
This is not a toll-free number, HUD
welcomes and is prepared to receive
calls from individuals who are deaf or
hard of hearing, as well as individuals
with speech or communication
disabilities. To learn more about how to
make an accessible telephone call,
please visit: https://www.fcc.gov/
consumers/guides/telecommunicationsrelay-service-trs. Copies of available
documents submitted to OMB may be
obtained from Ms. Guido.
[Docket No. FR–7070–N–89]
SUPPLEMENTARY INFORMATION:
Development Stage
Clinical development.
Dated: November 30, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–26736 Filed 12–5–23; 8:45 am]
BILLING CODE 4140–01–P
30-Day Notice of Proposed Information
Collection: Labor Standards Deposit
Account Voucher, OMB Control No.:
2501–0021
Office of Policy Development
and Research, Chief Data Officer, HUD.
ACTION: Notice.
AGENCY:
HUD is seeking approval from
the Office of Management and Budget
(OMB) for the information collection
described below. In accordance with the
Paperwork Reduction Act, HUD is
requesting comment from all interested
parties on the proposed collection of
information. The purpose of this notice
is to allow for an additional 30 days of
public comment.
DATES: Comments Due Date: January 5,
2024.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Interested persons are
also invited to submit comments
regarding this proposal and comments
should refer to the proposal by name
and/or OMB Control Number and
should be sent to: Anna Guido,
Clearance Officer, REE, Department of
Housing and Urban Development, 451
7th Street SW, Room 8210, Washington,
DC 20410–5000; email
PaperworkReductionActOffice@
hud.gov.
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
This
notice informs the public that HUD is
seeking approval from OMB for the
information collection described in
Section A.
The Federal Register notice that
solicited public comment on the
information collection for a period of 60
days was published on August 4, 2023
at 88 FR 51847.
A. Overview of Information Collection
Title of Information Collection: Labor
Standards Deposit Account Voucher.
OMB Approval Number: 2501–0021.
Type of Request: This is an extension
of a currently approved collection.
Form Number: HUD–4734.
Description of the need for the
information and proposed use: HUD,
State, Local and Tribal housing agencies
administrating HUD-assisted programs
must enforce Federal Labor Standards
requirements, including the payment of
prevailing wage rates to laborers and
mechanics employed on HUD-assisted
construction and maintenance work that
is covered by these requirements.
Enforcement activities include securing
funds to ensure the payment of wage
restitution that has been or may be
found due to laborers and mechanics
who were employed on HUD-assisted
projects. Also, funds ae collected for the
payment to the U.S. Treasury of
liquidated damages that were assessed
for violations of Contract Work Hours
and Safety Standards Act (CWHSSA). If
the labor standards discrepancies are
resolved, HUD refunds associated
amounts to the depositor. As underpaid
laborers and mechanics are located,
HUD sends wage restitution payments
to the workers.
E:\FR\FM\06DEN1.SGM
06DEN1
]]>Agencies
[Federal Register Volume 88, Number 233 (Wednesday, December 6, 2023)]
[Notices]
[Pages 84823-84824]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26736]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is directed to a device to measure
placental oxygen saturation in pregnant women from 20 weeks of
pregnancy to delivery. The device monitors maternal tissue oxygen
saturation, blood oxygen saturation, breathing rate, heart rate, and
heart rate variability from signal, fetal movement activity and
potentially fetal heart rate and heart rate variability. This
technology was discovered and is being developed by the National
Institute on Child Health and Human Development (NICHD). The NICHD is
currently seeking a licensee and/or collaborator to further develop
this technology.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
and collaboration opportunity should be directed to: Zarpheen Jinnah,
Technology Transfer Manager, NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892-9702 (for
business mail), Rockville, MD 20850-9702. Telephone: (240)-276-5530;
[[Page 84824]]
Facsimile: (240)-276-5504; Email: [email protected]. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to this invention.
SUPPLEMENTARY INFORMATION: The following patent application is
available for licensing and/or collaboration under a Cooperative
Research and Development Agreement (CRADA):
US Provisional Application No. 63/451,066.
Achieving expeditious commercialization of federally funded
research and development is consistent with the goals of the Bayh-Dole
Act, codified as 35 U.S.C. 200-212.
Background and Description of Technology
Monitoring placental oxygenation level and maternal physiological
signals can be useful to assess mother and fetus well-being during
pregnancy. Additionally, fetal movement has long served as a measure
for fetal well-being and nervous system development helping to identify
adverse pregnancy outcomes. Identification of complications during
pregnancy can allow for earlier interventions, including medications to
reduce risk of perinatal mortality and maternal gene therapy.
Researchers at NICHD have created a wearable and wireless device and
protocol for continuously monitoring the placental oxygenation levels,
multiple physiological signals and movement activities of a fetus and
mother. The device includes a compact control board, a flexible near-
infrared spectroscopy (NIRS) probe, and multiple accelerator probes. A
classification algorithm based on Monte-Carlo simulations of multiple
layers model computes oxygen saturation of the placenta. There are one
or more accelerator probes attached to different body parts of the
mother to detect mother movement activities and to eliminate the effect
of mother movement on fetal movement. The overall data acquisition rate
of this device is 10 Hz or more. With this acquisition rate, the output
of the device contains extra physiological signal such as maternal
respiratory and cardiac functions, and fetal cardiac functions.
Potential Commercial Applications
A low cost wearable device, similar to a smart watch, in which a
pregnant woman can wear regularly to monitor both mother and fetus
health conditions.
Competitive Advantages:
Wearable and non-invasive placenta and fetal monitoring
device.
Capable of 24/7 continuous monitoring of mother and fetal
well-being.
Development Stage
Clinical development.
Dated: November 30, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-26736 Filed 12-5-23; 8:45 am]
BILLING CODE 4140-01-P
